169 related articles for article (PubMed ID: 19541764)
1. Use of combined androgen blockade for advanced prostate cancer in British Columbia.
Chau A; de Lemos ML; Pickles T; Blood P; Kovacic L; Abadi S; Barnett J
J Oncol Pharm Pract; 2010 Jun; 16(2):121-6. PubMed ID: 19541764
[TBL] [Abstract][Full Text] [Related]
2. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
3. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?
Krahn M; Bremner KE; Tomlinson G; Luo J; Ritvo P; Naglie G; Alibhai SM
BJU Int; 2011 Nov; 108(10):1588-96. PubMed ID: 21453344
[TBL] [Abstract][Full Text] [Related]
5. Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?
Oh WK; Landrum MB; Lamont EB; McNeil BJ; Keating NL
Urology; 2010 Mar; 75(3):642-7. PubMed ID: 19962733
[TBL] [Abstract][Full Text] [Related]
6. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
Akaza H
BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
[TBL] [Abstract][Full Text] [Related]
7. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
8. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
Maekawa S; Maegawa M; Ushida H; Inoue K; Kaneko Y; Ohmori K; Nishimura K
Hinyokika Kiyo; 2001 Aug; 47(8):553-5. PubMed ID: 11579594
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
Bayoumi AM; Brown AD; Garber AM
J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616
[TBL] [Abstract][Full Text] [Related]
10. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
Penson DF; Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M
J Urol; 2005 Aug; 174(2):547-52; discussion 552. PubMed ID: 16006889
[TBL] [Abstract][Full Text] [Related]
12. Maximal androgen blockade for advanced prostate cancer.
Klotz L
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
[TBL] [Abstract][Full Text] [Related]
13. Intra-prostatic androgen levels during various androgen-blockade regimens.
Nishiyama T
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
[TBL] [Abstract][Full Text] [Related]
14. Primary combined androgen blockade in localized disease and its mechanism.
Namiki M; Kitagawa Y; Mizokami A; Koh E
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):303-15. PubMed ID: 18471788
[TBL] [Abstract][Full Text] [Related]
15. [The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer].
Ito T; Aizawa T; Yamamoto S; Ohkubo Y; Tsujino S; Miki M
Hinyokika Kiyo; 1998 Jul; 44(7):477-80. PubMed ID: 9752601
[TBL] [Abstract][Full Text] [Related]
16. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
17. [Monotherapy versus combined androgen blockade for advanced/metastatic prostate cancer].
Iida K
Gan To Kagaku Ryoho; 2011 Dec; 38(13):2553-7. PubMed ID: 22189220
[TBL] [Abstract][Full Text] [Related]
18. [Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].
Matveev BP; Bukharkin BV
Vopr Onkol; 1998; 44(5):537-40. PubMed ID: 9884710
[TBL] [Abstract][Full Text] [Related]
19. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
20. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
